OncoMed Pharmaceuticals Announces Proposed Public Offering

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OncoMed Pharmaceuticals Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Aug. 17, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED ), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by OncoMed. In addition, OncoMed intends to grant to the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares sold in the offering, on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

OncoMed expects to use its existing cash, cash equivalents and short-term investments and the net proceeds from the offering for general corporate purposes, which may include, among other things, increasing its working capital, funding research and development, including its wholly-owned GITRL-Fc immuno-oncology program, and capital expenditures.

Leerink Partners LLC is acting as sole book-running manager for the proposed offering.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on July 22, 2015. The offering is being made only by means of a prospectus supplement filed today with the SEC. Copies of the preliminary prospectus supplement relating to this offering may be obtained by contacting Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37 th  Floor, Boston, MA, 02110, by email at  syndicate@leerink.com , or by telephone at (800) 808-7525, ext. 6142.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

About OncoMed Pharmaceuticals OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics.  OncoMed has seven anti-cancer therapeutic candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR.  OncoMed is advancing its wholly owned GITRL-Fc candidate and an undisclosed immuno-oncology candidate (IO#2) toward clinical trials in the 2016-2017 timeframe. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK).

Forward-Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding OncoMed Pharmaceuticals, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995, including OncoMed’s expected use of the proceeds of the proposed offering, its future development plans for its product candidates and the timing and costs thereof. Such forward-looking statements involve substantial risks and uncertainties that could cause OncoMed’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all and the uncertainties inherent in research and the clinical development process. OncoMed undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to OncoMed’s business in general, please refer to OncoMed’s prospectus supplement filed with the Securities and Exchange Commission (SEC) on August 17, 2016, including the documents incorporated by reference therein, which include OncoMed’s Annual Report on Form 10-K filed with the SEC on March 10, 2016, OncoMed’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2016, and OncoMed’s other periodic reports filed with the SEC.

Contact: Michelle Corral Senior Director, Investor Relations and Corporate Communications OncoMed Pharmaceuticals michelle.corral@oncomed.com (650) 995-8373

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 70

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 59

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 100

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 115

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 36

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 72

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 62

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 120

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 116

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading

Top 5 Most Recently Viewed Articles

Westhaven Gold Secures $3.16 Million Investment for Growth

Updated Category News Views 128

Westhaven Gold Corp. Completes Strategic Private Placement Westhaven Gold Corp. (TSXV: WHN) has successfully closed a non-brokered private placement, raising a substantial $3.16 million to fuel its growth initiatives. This offering comprised the sale of units at a pivotal time for the company, allowing it to enhance its exploration and development capabilities. Details of...

Continue Reading
Revolutionizing Social Media: Alexis Ohanian and Kevin Rose Join Forces

Updated Category News Views 290

Reviving a Social Media Pioneer: Ohanian and Rose Unite In a surprising turn of events, social media titans Kevin Rose and Alexis Ohanian have teamed up to acquire the pioneering social platform, Digg. Both are recognized as early influencers in the tech industry, having co-founded some of the most notable platforms of the early web era. Now, their mission is clear: to...

Continue Reading
Exploring Innovation in CBA's Tech Ecosystem for 2024

Updated Category News Views 1337

Unveiling the Commonwealth Bank of Australia's Tech Innovations In the ever-evolving landscape of finance and technology, Commonwealth Bank of Australia (CBA) stands out as a leader. Their commitment to embracing digital transformation is not just a business strategy; it’s a comprehensive initiative that is reshaping how banking and financial services operate. The...

Continue Reading
Sheralven and Game On Team Up for Messi's Signature Fragrance

Updated Category News Views 167

Sheralven and Game On Join Forces for Messi Fragrance Launch In an exciting partnership that combines sports and beauty, Sheralven, a leader in the beauty industry, has teamed up with Game On Product Group to exclusively distribute the much-anticipated Messi Eau de Parfum in North America. This marks a significant collaboration as the fragrance is the first signature...

Continue Reading
CK Health Plus Secures Direct Selling License in Malaysia

Updated Category News Views 176

CK Health Plus Achieves Milestone in Malaysia CK Health Plus Sdn. Bhd., a subsidiary of EUDA Health Holdings Limited (NASDAQ: EUDA), has recently achieved a significant milestone by securing a Direct Selling License in Malaysia. This achievement reinforces the Company’s commitment to expanding its non-invasive healthcare offerings across Asia. Understanding the...

Continue Reading